Bluejay Diagnostics, Inc. BJDX
At closeNov 9, 2026, 6:06 AM EST
Pre-market · Nov 9, 6:06 AM ET
- YTD
- -77.98%
- 1 year
- -90.76%
- Market cap
- 2.62M
- EPS (ttm)
- -14.32
- Shares out
- 552.85K
- Forward P/E
- -11.88
- YTD return
- -77.98%
- 1-year return
- -90.76%
- Volume
- 15.38K
- Avg volume
- 335.30K
- Open
- 2.22
- Previous close
- 2.19
- Day's range
- 2.22 – 2.41
- 52-week range
- 1.84 – 28.00
- Beta
- 0.73
- Earnings date
- May 15, 2024
5D +0.26 (+12.44%)
Key statistics
- Enterprise value
- -7.04M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.49M
- Total cash
- 8.06M
- Total debt
- 442.13K
- Return on equity
- -125.25%
- Short % of float
- 0.97%
- 50-day average
- 4.46
- 200-day average
- 96.26
Next earnings
May 15, 2024
Expected May 15, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -8.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -256.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -272.00 | -712.00 | -440.00 | -161.76% |
| Nov 9, 2023 | Sep 1, 2023 | -328.00 | -832.00 | -504.00 | -153.66% |
| Aug 14, 2023 | Jun 1, 2023 | -600.00 | -1,100.00 | -500.00 | -83.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 2023 | Dawson James | down | Buy | Neutral |
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bluejaydx.com
News
Your note
Sign in to keep a note on BJDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHASE DONALD R | Director | Stock Award(Grant) | Jan 31, 2023 | 792,852 |
| DEY INDRANIL | Chief Executive Officer | Purchase | Dec 12, 2023 | 233,093 |
| DEY SVETLANA | Director | Purchase | Dec 12, 2023 | 206,067 |
| FISHER KENNETH R | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2023 | 113,184 |
| GEMIGNANI GARY G | Director | Stock Award(Grant) | Jan 31, 2023 | 27,500 |
| WURTH DOUGLAS CLARK | Director | Stock Award(Grant) | Jan 31, 2023 | 2,313,850 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 1.16% | 6,386 | 24.27K | Sep 29, 2024 |
| Sabby Management, LLC | 1.10% | 6,104 | 23.20K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.50% | 2,740 | 10.41K | Sep 29, 2024 |
| CVI Holdings, LLC | 0.24% | 1,323 | 5.03K | Jun 29, 2024 |
| UBS Group AG | 0.22% | 1,229 | 4.67K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.19% | 1,053 | 4.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.07% | 403 | 1.53K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 1 | 3 | Oct 30, 2024 |